FLORINEF Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Florinef, and what generic alternatives are available?
Florinef is a drug marketed by Casper Pharma Llc and is included in one NDA.
The generic ingredient in FLORINEF is fludrocortisone acetate. There are four drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the fludrocortisone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Florinef
A generic version of FLORINEF was approved as fludrocortisone acetate by IMPAX LABS on March 18th, 2002.
Summary for FLORINEF
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 38 |
Clinical Trials: | 7 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FLORINEF at DailyMed |
Recent Clinical Trials for FLORINEF
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tehran Arrhythmia Center | Phase 3 |
Mahidol University | Phase 3 |
Tehran Heart Center | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for FLORINEF
US Patents and Regulatory Information for FLORINEF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Casper Pharma Llc | FLORINEF | fludrocortisone acetate | TABLET;ORAL | 010060-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |